Cowen and Company’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Cowen and Company’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-250,974	Closed	-$4.47K	–	780
2022 Q4	$4.47K	Hold	250,974	–	–	﹤0.01%	504
2022 Q3	$21K	Buy	250,974 +32,691	+15%	+$3.5K	﹤0.01%	344
2022 Q2	$17K	Buy	218,283 +92,233	+73%	+$15.9K	﹤0.01%	424
2022 Q1	$25K	Buy	126,050 +37,887	+43%	+$11.4K	﹤0.01%	408
2021 Q4	$48K	Buy	88,163 +33,091	+60%	+$18.8K	﹤0.01%	447
2021 Q3	$33K	Buy	+55,072	New	+$37K	﹤0.01%	429

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Cowen and Company's IBER.WS Position: Q1 2023 in Review

Cowen and Company sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 250,974 shares — an estimated $4.47K sold.

Cowen and Company first reported a position in IBER.WS in Q3 2021 and held it in 6 quarters. The position peaked at $48K in Q4 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Cowen and Company reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 250,974 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $4.47K.
Cowen and Company first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q3 2021 and held it in 6 quarters.
Cowen and Company's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $48K in Q4 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.